LATEST NEWS

u-blox enters worldwide patent license agreement with Philips for 2G, 3G and 4G products

Thalwil, Switzerland – September 28, 2018 – u-blox (SIX:UBXN), a global provider of leading positioning and wireless communication technologies, today announced that it has entered into a worldwide, non-exclusive, patent license agreement with KONINKLIJKE PHILIPS N.V. (Philips) covering the sale by u-blox AG (u-blox) of its 2G, 3G, and 4G products for a defined term.

“u-blox respects the intellectual property rights of others and has always been and continues to be a willing licensee to standard-essential patents (SEPs)”, said Thomas Seiler, CEO of u-blox.  “In fact, u-blox views this as a value-added differentiator that benefits u-blox customers and positively distinguishes u-blox within the module industry.  u-blox remains committed to this strategy – it’s how we do business.”

Liat

Recent Posts

Tower Semiconductor Secures $1.3 Billion Silicon Photonics Agreements and Reports Strong Q1 2026 Growth

Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…

6 hours ago

14 Israeli Cybersecurity Companies Named to the Rising in Cyber 2026 List of the World’s Most Promising Cyber Startups

The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…

7 hours ago

Sequent Selected by 15 Canadian Municipalities to Deliver Verifiable, Trust-Based Digital Voting for Elections

More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…

7 hours ago

Sheba and Ichilov Medical Centers Join AccuLine’s International Clinical Trial for AI-Driven Early Heart Attack Risk Assessment

The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…

7 hours ago

Molex Completes Acquisition of Teramount Ltd.

Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…

3 days ago

Immunai Expands Oncology Collaboration, Extending AI-Driven Biomarker and Clinical Insights Through 2027

This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…

3 days ago